1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 05/16 10:59:45 am
735 DKK   -1.88%
12:08pEuropean ADRs Move Higher in Monday Trading
MT
10:05aNOVO NORDISK A/S : Share repurchase programme
GL
10:05aNOVO NORDISK A/S : Share repurchase programme
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVO NORDISK : Gets a Neutral rating from JP Morgan

01/04/2022 | 03:31am EDT

JP Morgan confirms his opinion on the stock and remains Neutral. The target price is unchanged and still at DKK 700.


ę MarketScreener with dpa-AFX Analyser 2022
All news about NOVO NORDISK A/S
12:08pEuropean ADRs Move Higher in Monday Trading
MT
10:05aNOVO NORDISK A/S : Share repurchase programme
GL
10:05aNOVO NORDISK A/S : Share repurchase programme
GL
05/13U.S. FDA approves Eli Lilly's treatment for type 2 diabetes
RE
05/12NOVO NORDISK : Barclays gives a Buy rating
MD
05/11NOVO NORDISK A/S : Trading in Novo Nordisk shares by board members, executives and associa..
GL
05/11NOVO NORDISK : Deutsche Bank keeps its Buy rating
MD
05/10Novo Nordisk Starts Research Collaboration With Flagship Pioneering
MT
05/09Novo Nordisk - major shareholder announcement
AQ
05/06NOVO NORDISK A/S :
GL
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 166 B 23 154 M 23 154 M
Net income 2022 52 637 M 7 360 M 7 360 M
Net cash 2022 4 087 M 571 M 571 M
P/E ratio 2022 31,5x
Yield 2022 1,56%
Capitalization 1 670 B 233 B 233 B
EV / Sales 2022 10,1x
EV / Sales 2023 8,88x
Nbr of Employees 49 295
Free-Float 69,6%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 735,00 DKK
Average target price 787,92 DKK
Spread / Average Target 7,20%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S0.00%238 221
JOHNSON & JOHNSON3.38%465 363
PFIZER, INC.-15.46%280 096
ABBVIE INC.13.37%271 251
ELI LILLY AND COMPANY5.58%262 514
ROCHE HOLDING AG-15.85%258 421